Guo-Sheng Wang1, Yan-Gang Huang1, Huan Li2, Shi-Jie Bi1, Jin-Long Zhao1. 1. The First Affiliated Hospital of Harbin Medical University 23 Youzheng Str, Nangang District, Harbin 150001, Heilongjiang Province, P. R. China. 2. School of Medicine, Shenzhen University Nanhai Ave 3688, Shenzhen 518060, Guangdong Province, China.
Abstract
OBJECTIVE: 17β-estradiol (E2) exerts its functions through both genomic and non-genomic signaling pathways. Because E2 is important in breast cancer development, we investigated whether its actions in promoting breast cancer cell proliferation occur through the non-genomic signaling pathway via extracellular signal-regulated kinase 1/2 (ERK1/2)/calcium-activated neutral protease (CANP). METHODS: MCF-7 breast cancer cells were treated with ERKl/2 inhibitor (PD98059) or CANP inhibitor (calpeptin) before exposure to 1×10(-8) M E2. MTT colorimetry and flow cytometry were used to analyze effects on cell proliferation and cell cycle progression, respectively. Expression of phosphorylated-ERK (p-ERK), total ERK, and Capn4 proteins were assessed by Western blotting. RESULTS: Cell proliferation increased in cells treated with E2 for 24 h (P<0.05), and the proportion of cells in G0/G1 was decreased, accompanied by accelerated G1/S. Calpeptin pre-treatment significantly inhibited the E2-induced proliferation of MCF-7 cells (P<0.05), while also ameliorating the effects of E2 on cell cycle progression. Further, expression of p-ERK was rapidly up-regulated (after 10 min) by E2 (P<0.05), an effect that persisted 16 h after E2 exposure but which was significantly inhibited by PD98059 (P<0.05). CONCLUSIONS: Finally, expression of Capn4 protein was rapidly up-regulated in E2-exposed cells (P<0.05), but this change was significantly inhibited by PD98059 or calpeptin (P<0.05) pre-treatment. Thus, the rapid, non-genomic ERK/CANP signaling pathway mediates E2-induced proliferation of human breast cancer cells.
OBJECTIVE: 17β-estradiol (E2) exerts its functions through both genomic and non-genomic signaling pathways. Because E2 is important in breast cancer development, we investigated whether its actions in promoting breast cancer cell proliferation occur through the non-genomic signaling pathway via extracellular signal-regulated kinase 1/2 (ERK1/2)/calcium-activated neutral protease (CANP). METHODS: MCF-7 breast cancer cells were treated with ERKl/2 inhibitor (PD98059) or CANP inhibitor (calpeptin) before exposure to 1×10(-8) M E2. MTT colorimetry and flow cytometry were used to analyze effects on cell proliferation and cell cycle progression, respectively. Expression of phosphorylated-ERK (p-ERK), total ERK, and Capn4 proteins were assessed by Western blotting. RESULTS: Cell proliferation increased in cells treated with E2 for 24 h (P<0.05), and the proportion of cells in G0/G1 was decreased, accompanied by accelerated G1/S. Calpeptin pre-treatment significantly inhibited the E2-induced proliferation of MCF-7 cells (P<0.05), while also ameliorating the effects of E2 on cell cycle progression. Further, expression of p-ERK was rapidly up-regulated (after 10 min) by E2 (P<0.05), an effect that persisted 16 h after E2 exposure but which was significantly inhibited by PD98059 (P<0.05). CONCLUSIONS: Finally, expression of Capn4 protein was rapidly up-regulated in E2-exposed cells (P<0.05), but this change was significantly inhibited by PD98059 or calpeptin (P<0.05) pre-treatment. Thus, the rapid, non-genomic ERK/CANP signaling pathway mediates E2-induced proliferation of humanbreast cancer cells.
Entities:
Keywords:
Breast cancer cell; cell proliferation; estradiol; extracellular signal-regulated kinase
Authors: Masako Shimada; Peter A Greer; Andrew P McMahon; Mary L Bouxsein; Ernestina Schipani Journal: J Biol Chem Date: 2008-05-30 Impact factor: 5.157
Authors: Sohila Zadran; Qingyu Qin; Xiaoning Bi; Homera Zadran; Young Kim; Michael R Foy; Richard Thompson; Michel Baudry Journal: Proc Natl Acad Sci U S A Date: 2009-12-07 Impact factor: 11.205
Authors: A Glading; R J Bodnar; I J Reynolds; H Shiraha; L Satish; D A Potter; H C Blair; A Wells Journal: Mol Cell Biol Date: 2004-03 Impact factor: 4.272